Corium International Inc. (NASDAQ:CORI) shares saw unusually-strong trading volume on Friday . Approximately 80,982 shares were traded during trading, an increase of 23% from the previous session’s volume of 65,978 shares.The stock last traded at $6.25 and had previously closed at $6.85.

Several equities research analysts have recently weighed in on CORI shares. FBR & Co reiterated a “buy” rating on shares of Corium International in a research report on Thursday, June 16th. Leerink Swann reiterated a “buy” rating and set a $14.00 price objective on shares of Corium International in a research report on Wednesday, May 18th. Jefferies Group reiterated a “buy” rating and set a $9.00 price objective on shares of Corium International in a research report on Wednesday, May 11th. Zacks Investment Research upgraded shares of Corium International from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a research report on Tuesday, July 19th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $15.00 price objective on shares of Corium International in a research report on Thursday, June 23rd. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $11.92.

The stock has a 50-day moving average of $4.67 and a 200 day moving average of $4.37. The company’s market cap is $138.40 million.

Corium International (NASDAQ:CORI) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.08. On average, equities research analysts predict that Corium International Inc. will post ($1.63) EPS for the current year.

Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.